Supplementary
Candidate compounds that target the HSF-1 pathway to modulate HSP levels. Suspected molecular targets are listed in parentheses below the name of each chemical shown to induce expression of the listed HSPs in cell/animal models [1] . Chemical treatment also modulates molecular events associated with tauopathy and other neurodegenerative proteinopathies. 17-AAG, 17-allyl-amino-geldanamycin; p-tau, hyperphosphorylated tau. htt-polyQ, polyglutamine expanded huntingtin protein. Agg, protein aggregate. *This effect, dependent upon de novo hsp70 induction, was for the 17-AAG parent compound geldanamycin. Other listed effects on tau pathology were shown to be independent of de-novo HSP induction [2, 3] . † Association between hsp27/70 induction and modulation of htt-polyQ aggregation in vitro (unpublished observations of M. Duennwald, personal communication, 2009). Withaferin-A is generally described and characterized in reference [15] . Polarity score is based upon 'topological polar surface area', which is calculated based upon the number of N-or O-containing moieties, taking hybridizations, charges, and participation of aromatic systems into account but ignoring 3D coordinates of each group. It has been estimated from empirical analyses that compounds with a polarity of less than 60 are best absorbed across intestinal epithelia and the human blood-brain barrier by passive diffusion. Conversely, compounds with a polarity above 120 or 140 are poorly absorbed across the blood-brain barrier and intestinal epithelia respectively [16, 17] . Examples of receptor or carrier-mediated processes that allow passage of more polar molecules across these barriers are known, however. 

